180 related articles for article (PubMed ID: 21030860)
1. Immunohistochemical and molecular markers in breast phyllodes tumors.
Korcheva VB; Levine J; Beadling C; Warrick A; Countryman G; Olson NR; Heinrich MC; Corless CL; Troxell ML
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):119-25. PubMed ID: 21030860
[TBL] [Abstract][Full Text] [Related]
2. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
3. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study.
Tan PH; Jayabaskar T; Yip G; Tan Y; Hilmy M; Selvarajan S; Bay BH
Mod Pathol; 2005 Dec; 18(12):1527-34. PubMed ID: 16258510
[TBL] [Abstract][Full Text] [Related]
4. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
5. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
6. Comparison of stromal CD10 expression in benign, borderline, and malignant phyllodes tumors among Egyptian female patients.
Ibrahim WS
Indian J Pathol Microbiol; 2011; 54(4):741-4. PubMed ID: 22234101
[TBL] [Abstract][Full Text] [Related]
7. Patterns of p53 expression in phyllodes tumors of the breast--an immunohistochemical study.
Kim CJ; Kim WH
J Korean Med Sci; 1993 Oct; 8(5):325-8. PubMed ID: 8305139
[TBL] [Abstract][Full Text] [Related]
8. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
[TBL] [Abstract][Full Text] [Related]
10. Utility of Ki-67, CD10, CD34, p53, CD117, and mast cell content in the differential diagnosis of cellular fibroadenomas and in the classification of phyllodes tumors of the breast.
Vilela MH; de Almeida FM; de Paula GM; Ribeiro NB; Cirqueira MB; Silva AL; Moreira MA
Int J Surg Pathol; 2014 Sep; 22(6):485-91. PubMed ID: 24492332
[TBL] [Abstract][Full Text] [Related]
11. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
Kuijper A; de Vos RA; Lagendijk JH; van der Wall E; van Diest PJ
Am J Clin Pathol; 2005 May; 123(5):690-8. PubMed ID: 15981808
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
13. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
Kucuk U; Bayol U; Pala EE; Cumurcu S
Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Molecular and Biological Characteristics of Phyllodes Tumors of the Breast.
Vorotnikov IK; Vysotskaya IV; Denchik DA; Letyagin VP; Davydov MM; Kirsanov VY; Kim EA; Buseva VS
Bull Exp Biol Med; 2020 Oct; 169(6):806-810. PubMed ID: 33098518
[TBL] [Abstract][Full Text] [Related]
15. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Gatalica Z; Vranic S; Ghazalpour A; Xiu J; Ocal IT; McGill J; Bender RP; Discianno E; Schlum A; Sanati S; Palazzo J; Reddy S; Pockaj B
Oncotarget; 2016 Jan; 7(2):1707-16. PubMed ID: 26625196
[TBL] [Abstract][Full Text] [Related]
16. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
17. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast.
Huang KT; Dobrovic A; Yan M; Karim RZ; Lee CS; Lakhani SR; Fox SB
Breast Cancer Res Treat; 2010 Nov; 124(2):555-65. PubMed ID: 20563638
[TBL] [Abstract][Full Text] [Related]
19. MED12 exon 2 mutations in phyllodes tumors of the breast.
Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
[TBL] [Abstract][Full Text] [Related]
20. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases.
Niezabitowski A; Lackowska B; Rys J; Kruczak A; Kowalska T; Mitus J; Reinfuss M; Markiewicz D
Breast Cancer Res Treat; 2001 Jan; 65(1):77-85. PubMed ID: 11245343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
